{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:55:21Z","timestamp":1778745321207,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Current continuous kidney replacement therapy (CKRT) protocols ignore physiological renal compensation for hypercapnia. This study aimed to explore feasibility, safety, and clinical benefits of pCO2-adapted CKRT for hypercapnic acute respiratory distress syndrome (ARDS) patients with indication for CKRT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We enrolled mechanically ventilated hypercapnic ARDS patients (pCO2\u2009&gt;\u20097.33\u00a0kPa) receiving regional citrate anticoagulation (RCA) based CKRT in a prospective, randomized-controlled pilot-study across five intensive care units at the Charit\u00e9\u2014Universit\u00e4tsmedizin Berlin, Germany. Patients were randomly assigned 1:1 to the control group with bicarbonate targeted to 24\u00a0mmol\/l or pCO<jats:sub>2<\/jats:sub>-adapted-CKRT with target bicarbonate corresponding to physiological renal compensation. Study duration was six days. Primary outcome was bicarbonate after 72\u00a0h. Secondary endpoints included safety and clinical endpoints. Endpoints were assessed in all patients receiving treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From September 2021 to May 2023 40 patients (80% male) were enrolled. 19 patients were randomized to the control group, 21 patients were randomized to pCO<jats:sub>2<\/jats:sub>-adapted-CKRT. Five patients were excluded before receiving treatment: three in the control group (consent withdrawal, lack of inclusion criteria fulfillment (n\u2009=\u20092)) and two in the intervention group (lack of inclusion criteria fulfillment, sudden unexpected death) and were therefore not included in the analysis. Median plasma bicarbonate 72\u00a0h after randomization was significantly higher in the intervention group (30.70\u00a0mmol\/l (IQR 29.48; 31.93)) than in the control group (26.40\u00a0mmol\/l (IQR 25.63; 26.88); <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). More patients in the intervention group received lung protective ventilation defined as tidal volume\u2009&lt;\u20098\u00a0ml\/kg predicted body weight. Thirty-day mortality was 10\/16 (63%) in the control group vs. 8\/19 (42%) in the intervention group (<jats:italic>p<\/jats:italic>\u2009=\u20090.26).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Tailoring CKRT to physiological renal compensation of respiratory acidosis appears feasible and safe with the potential to improve patient care in hypercapnic ARDS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>The trial was registered in the German Clinical Trials Register (DRKS00026177) on September\u00a09,\u00a02021 and is now closed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-024-04979-z","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T15:27:06Z","timestamp":1718119626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Standard vs. carbone dioxide adapted kidney replacement therapy in hypercapnic ARDS patients: a randomized controlled pilot trial (BigBIC)"],"prefix":"10.1186","volume":"28","author":[{"given":"Julius Valentin","family":"Kunz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Hansmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareike","family":"F\u00e4hndrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mareen","family":"Pigorsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Bethke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harm","family":"Peters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Kr\u00fcger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Marcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abakar","family":"Magomedov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"M\u00fcller-Redetzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmytro","family":"Khadzhynov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Enghard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"issue":"7","key":"4979_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00134-023-07050-7","volume":"49","author":"G Grasselli","year":"2023","unstructured":"Grasselli G, Calfee CS, Camporota L, et al. ESICM guidelines on acute respiratory distress syndrome: definition, phenotyping and respiratory support strategies. Intensive Care Med. 2023;49(7):727\u201359.","journal-title":"Intensive Care Med"},{"issue":"1","key":"4979_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000420","volume":"6","author":"MJD Griffiths","year":"2019","unstructured":"Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1): e000420.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"4979_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/ki.2011.243","volume":"82","author":"J Cerd\u00e1","year":"2012","unstructured":"Cerd\u00e1 J, Tolwani AJ, Warnock DG. Critical care nephrology: management of acid\u2013base disorders with CRRT. Kidney Int. 2012;82(1):9\u201318.","journal-title":"Kidney Int"},{"issue":"5","key":"4979_CR4","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ekir.2018.06.001","volume":"3","author":"SB Gonz\u00e1lez","year":"2018","unstructured":"Gonz\u00e1lez SB, Menga G, Raimondi GA, Tighiouart H, Adrogu\u00e9 HJ, Madias NE. Secondary response to chronic respiratory acidosis in humans: a prospective study. Kidney Int Rep. 2018;3(5):1163\u201370.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"4979_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13613-019-0552-5","volume":"9","author":"A Panitchote","year":"2019","unstructured":"Panitchote A, Mehkri O, Hastings A, et al. Factors associated with acute kidney injury in acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):74.","journal-title":"Ann Intensive Care"},{"issue":"1","key":"4979_CR6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4037\/ajcc2018901","volume":"27","author":"CJ Tignanelli","year":"2018","unstructured":"Tignanelli CJ, Wiktor AJ, Vatsaas CJ, et al. Outcomes of acute kidney injury in patients with severe ARDS due to influenza A(H1N1) pdm09 virus. Am J Crit Care. 2018;27(1):67\u201373.","journal-title":"Am J Crit Care"},{"issue":"1","key":"4979_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.2215\/CJN.00040505","volume":"1","author":"AJ Tolwani","year":"2006","unstructured":"Tolwani AJ, Prendergast MB, Speer RR, Stofan BS, Wille KM. A practical citrate anticoagulation continuous venovenous hemodiafiltration protocol for metabolic control and high solute clearance. Clin J Am Soc Nephrol. 2006;1(1):79\u201387.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4979_CR8","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/CCM.0b013e3181a00a92","volume":"37","author":"S Morgera","year":"2009","unstructured":"Morgera S, Schneider M, Slowinski T, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009;37(6):2018\u201324.","journal-title":"Crit Care Med"},{"issue":"4","key":"4979_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1177\/039139880803100414","volume":"31","author":"D Kindgen-Milles","year":"2008","unstructured":"Kindgen-Milles D, Amman J, Kleinekofort W, Morgera S. Treatment of metabolic alkalosis during continuous renal replacement therapy with regional citrate anticoagulation. Int J Artif Organs. 2008;31(4):363\u20136.","journal-title":"Int J Artif Organs"},{"issue":"23","key":"4979_CR10","first-page":"2526","volume":"307","author":"VM Ranieri","year":"2012","unstructured":"Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526\u201333.","journal-title":"JAMA"},{"issue":"2","key":"4979_CR11","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcrc.2013.10.015","volume":"29","author":"D Khadzhynov","year":"2014","unstructured":"Khadzhynov D, Schelter C, Lieker I, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care. 2014;29(2):265\u201371.","journal-title":"J Crit Care"},{"issue":"1","key":"4979_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13054-015-1066-7","volume":"19","author":"T Slowinski","year":"2015","unstructured":"Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the liver citrate anticoagulation threshold (L-CAT) observational study. Crit Care. 2015;19(1):349.","journal-title":"Crit Care"},{"issue":"1","key":"4979_CR13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.32614\/RJ-2023-029","volume":"15","author":"F Konietschke","year":"2003","unstructured":"Konietschke F, Pauly M, Bathke AC, Friedrich S, Brunner E. rankFD: an R software package for nonparametric analysis of general factorial designs. R JOURNAL. 2003;15(1):142\u201358.","journal-title":"R JOURNAL"},{"key":"4979_CR14","first-page":"1012","volume":"89","author":"P Calhoun","year":"2016","unstructured":"Calhoun P, Calhoun MP. Package \u2018exact.\u2019 J Am Stat Assoc. 2016;89:1012\u20136.","journal-title":"J Am Stat Assoc"},{"key":"4979_CR15","unstructured":"R Core Team, R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2022. https:\/\/www.R-project.org\/ (accessed 19 November 2023)."},{"issue":"4","key":"4979_CR16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1078-5337(03)00034-0","volume":"9","author":"RH Kallet","year":"2003","unstructured":"Kallet RH, Liu K, Tang J. Management of acidosis during lung-protective ventilation in acute respiratory distress syndrome. Respir Care Clin N Am. 2003;9(4):437\u201356.","journal-title":"Respir Care Clin N Am"},{"issue":"2","key":"4979_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1097\/MNH.0000000000000687","volume":"30","author":"R Chand","year":"2021","unstructured":"Chand R, Swenson ER, Goldfarb DS. Sodium bicarbonate therapy for acute respiratory acidosis. Curr Opin Nephrol Hypertens. 2021;30(2):223\u201330.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4979_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jcrc.2021.06.015","volume":"65","author":"S Shao","year":"2021","unstructured":"Shao S, Kang H, Qian Z, et al. Effect of different levels of PEEP on mortality in ICU patients without acute respiratory distress syndrome: systematic review and meta-analysis with trial sequential analysis. J Crit Care. 2021;65:246\u201358.","journal-title":"J Crit Care"},{"issue":"18","key":"4979_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","volume":"342","author":"RG Brower","year":"2000","unstructured":"Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301\u20138.","journal-title":"N Engl J Med"},{"issue":"23","key":"4979_CR20","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1056\/NEJMoa1214103","volume":"368","author":"C Gu\u00e9rin","year":"2013","unstructured":"Gu\u00e9rin C, Reignier J, Richard J-C, et al. Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013;368(23):2159\u201368.","journal-title":"N Engl J Med"},{"issue":"4","key":"4979_CR21","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/ki.1992.162","volume":"41","author":"T Symreng","year":"1992","unstructured":"Symreng T, Flanigan MJ, Lim VS. Ventilatory and metabolic changes during high efficiency hemodialysis. Kidney Int. 1992;41(4):1064\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"4979_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s40635-017-0141-6","volume":"5","author":"TG Romano","year":"2017","unstructured":"Romano TG, Azevedo LCP, Mendes PV, Costa ELV, Park M. Effect of continuous dialysis on blood ph in acidemic hypercapnic animals with severe acute kidney injury: a randomized experimental study comparing high vs. low bicarbonate affluent. Intensive Care Med Exp. 2017;5(1):28.","journal-title":"Intensive Care Med Exp"},{"issue":"4","key":"4979_CR23","doi-asserted-by":"publisher","first-page":"c211","DOI":"10.1159\/000088177","volume":"101","author":"S Morgera","year":"2005","unstructured":"Morgera S, Haase M, R\u00fcckert M, et al. Regional citrate anticoagulation in continuous hemodialysis\u2013acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract. 2005;101(4):c211\u20139.","journal-title":"Nephron Clin Pract"},{"issue":"9","key":"4979_CR24","doi-asserted-by":"publisher","first-page":"e941","DOI":"10.1097\/CCM.0000000000002501","volume":"45","author":"D Khadzhynov","year":"2017","unstructured":"Khadzhynov D, Dahlinger A, Schelter C, et al. Hyperlactatemia, lactate kinetics and prediction of citrate accumulation in critically Ill patients undergoing continuous renal replacement therapy with regional citrate anticoagulation. Crit Care Med. 2017;45(9):e941\u20136.","journal-title":"Crit Care Med"},{"issue":"2","key":"4979_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/MNH.0000000000000953","volume":"33","author":"A Israni","year":"2024","unstructured":"Israni A, Goldfarb DS. Let\u2019s stop talking about \u201ccitrate toxicity.\u201d Curr Opin Nephrol Hypertens. 2024;33(2):181\u20135.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"1","key":"4979_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13054-019-2317-9","volume":"23","author":"W Zhang","year":"2019","unstructured":"Zhang W, Bai M, Yu Y, et al. Safety and efficacy of regional citrate anticoagulation for continuous renal replacement therapy in liver failure patients: a systematic review and meta-analysis. Crit Care. 2019;23(1):22.","journal-title":"Crit Care"},{"key":"4979_CR27","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13054-015-1066-7","volume":"19","author":"T Slowinski","year":"2015","unstructured":"Slowinski T, Morgera S, Joannidis M, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the liver citrate anticoagulation threshold (L-CAT) observational study. Crit Care. 2015;19:349.","journal-title":"Crit Care"},{"issue":"9","key":"4979_CR28","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","volume":"8","author":"C Karagiannidis","year":"2020","unstructured":"Karagiannidis C, Mostert C, Hentschker C, et al. Case characteristics, resource use, and outcomes of 10021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020;8(9):853\u201362.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"4979_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1681\/ASN.2020060897","volume":"32","author":"S Gupta","year":"2021","unstructured":"Gupta S, Coca SG, Chan L, et al. AKI treated with renal replacement therapy in critically Ill patients with COVID-19. J Am Soc Nephrol. 2021;32(1):161\u201376.","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"4979_CR30","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1007\/s00134-022-06796-w","volume":"48","author":"A Combes","year":"2022","unstructured":"Combes A, Brodie D, Aissaoui N, et al. Extracorporeal carbon dioxide removal for acute respiratory failure: a review of potential indications, clinical practice and open research questions. Intensive Care Med. 2022;48(10):1308\u201321.","journal-title":"Intensive Care Med"},{"issue":"6","key":"4979_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1177\/0267659120906048","volume":"35","author":"T Staudinger","year":"2020","unstructured":"Staudinger T. Update on extracorporeal carbon dioxide removal: a comprehensive review on principles, indications, efficiency, and complications. Perfusion. 2020;35(6):492\u2013508.","journal-title":"Perfusion"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-024-04979-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-024-04979-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T15:28:37Z","timestamp":1718119717000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-024-04979-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4979"],"URL":"https:\/\/doi.org\/10.1186\/s13054-024-04979-z","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]},"assertion":[{"value":"8 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the local ethics committee (EA2\/101\/21). The study protocol can be found in the . The study was registered in the German Registry of Clinical Trials (DRKS00026177). The trial was conducted according to the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent was obtained from patients or their legal representatives. For patients incapable of giving consent and without a legal representative, urgent appointment of a legal guardian was requested. At inclusion, the attending physician was asked to confirm patient eligibility.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JVK received honoraria for lectures from NAW Berlin. KUE received honoraria from Astra Zeneca and Bayer for consultancy and lectures, as well as from Akebia and Otsuka for consultancy. DK received fees for speaking at a symposia organized on behalf of Fresenius Medical Care AG, Germany. For all other authors, there are no financial disclosures to declare. PE filed two patents for novel urinary biomarkers outside the submitted work. PE has received grants or contracts from the following entities: Deutsche Forschungsgemeinschaft (DFG), Jackst\u00e4dt Stiftung, Berliner Institut f\u00fcr Gesundheitsforschung (BIH), Bundesministerium f\u00fcr Bildung und Forschung (BMBF), Investitionsbank Berlin (IBB). Consulting fees include advisory roles for Glaxo Smith Klein (GSK), Bayer, and AstraZeneca. Payment or honoraria for lectures, presentations, speakers bureaus, and educational events were received from Akademie der Nieren, BDI Kickstarter, NAW Berlin, and Nachlese ASN Charit\u00e9. Support for attending meetings and travel was provided by Nachlese ASN Charit\u00e9 and AstraZeneca. Author PE has participated in an Advisory Board for Otsuka. PE serves as the spokesperson for the committee for intensive care of the German Society of Nephrology (DGfN). Stock or stock options have been received from Gilead.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"198"}}